This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
Unnamed facility
Gothenburg, Sweden
Change in height SDS (Standard Deviation Score) (referenced to normal population)
Time frame: From baseline until final height is reached
Final height SDS (referenced to normal population)
Time frame: From baseline until final height is reached
Final height SDS (referenced to Noonan population)
Time frame: From baseline until final height is reached
Change in height SDS (referenced to Noonan population)
Time frame: From baseline until final height is reached
Number of subjects with final height SDS above - 2SDS (reference to normal population)
Time frame: When final height is reached
Proportion of subjects with final height SDS above - 2SDS (reference to normal population)
Time frame: When final height is reached
Adverse events
Time frame: From baseline until final height is reached
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.